PYC Therapeutics Files Interim Results as RNA Pipeline Advances

PYC Therapeutics Limited ( (AU:PYC) ) has issued an announcement.

PYC Therapeutics Limited has lodged its Appendix 4D and interim financial statements for the half-year ended 31 December 2025 with the ASX. The release signals continued progression of the company’s clinical-stage RNA therapeutic programs and provides investors with updated financial disclosure as PYC advances its monogenic disease pipeline.

The board-approved filing underscores the company’s commitment to regulatory transparency as it develops its proprietary RNA drug delivery platform. Stakeholders will look to these interim accounts for insight into PYC’s funding position and operational runway amid a rapidly growing and commercially validated RNA therapeutics market.

The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.

More about PYC Therapeutics Limited

PYC Therapeutics Limited is a clinical-stage biotechnology company developing a new generation of RNA therapies for patients with genetic diseases. The company leverages a proprietary drug delivery platform to increase the potency of precision RNA medicines, with a focus on monogenic diseases that are considered to have a higher likelihood of success in clinical development.

Average Trading Volume: 790,467

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$1.41B

See more insights into PYC stock on TipRanks’ Stock Analysis page.